---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011177"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:40:23.094452+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q4 2025 preliminary revenue falls ~9% YoY; full year in line with guidance

## Summary
- Q4 2025 revenue $62.1M-$62.5M, down ~9% YoY at midpoint.
- Full-year 2025 revenue $212.3M-$212.7M, ~2% YoY growth, in line with $211M-$213M guidance.
- Added ~202 new active surgeons in 2025; total active surgeons ~3,337 (+6%).
- Not issuing FY 2026 guidance now; will provide during Q4 earnings call on Feb 26, 2026.
- CEO cites headwinds from broader economic conditions, softer consumer sentiment, product mix shift.

## SEC filing metadata
- accession: 0001193125-26-011177
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/0001193125-26-011177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/tmci-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011177
- JSON: https://secwatch.observer/filing/0001193125-26-011177.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.